This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Roekaerts, F. Articles by Deleers, L. Search for Related Content PubMed PubMed Citation Articles by Roekaerts, F. Articles by Deleers, L. Social Bookmarking                         What's this?

Trental® 400 in the Treatment of Intermittent Claudication: Results of Long-Term, Placebo-Controlled Administration

L. Deleers

A double-blind, randomized, placebo-controlled long-term clinical study of Trental® 400 was carried out, partly under cross-over design, partly as a parallel-group study, in 36 patients suffering from chronic arterial obstructive disorders in the lower limbs, associated with intermittent claudication, in order to evaluate the effectiveness and the safety of this drug administered t.i.d. over a period of 6 months. This controlled period was preceded by a placebo run-in period of 3 months. The clinical results under Trental 400 showed a statistically significant within group improvement of painfree and maximum walking parameters (p < 0.05) corresponding to an increase to baseline by + 96% to + 139% respectively and also in comparison to placebo (p < 0.05). The alterations of walking parameters within the placebo groups, ranging between -25% and +28% were not significant.

The subjective parameters (rest pain, paraesthesias, muscular cramps and sensation of heaviness in the legs) paralleled the course of the walking parameters. Under Trental 400, 24 out of 36 patients reported an improvement of these symptoms compared to 7 under placebo. Trental 400 was well tolerated. Minor side effects were mentioned by 7 out of 36 patients. One patient had to stop the drug treatment because of persisting prickling sensation and subsequent insomnia. Drug-related changes in the laboratory findings could not be detected; vital signs varied in function of age, concomitant drug treatments and seasonal factors. The results obtained in these studies suggest Trental 400 as a drug of choice for treating patients with intermittent claudication due to peripheral arterial obstruction according to stage II or III after Fontaine.

Angiology, Vol. 35, No. 7, 396-406 (1984)
DOI: 10.1177/000331978403500702


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Sobel and R. Verhaeghe Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 815S - 843S. [Abstract] [Full Text] [PDF]

				G. P. Clagett, M. Sobel, M. R. Jackson, G. Y. H. Lip, M. Tangelder, and R. Verhaeghe Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 609S - 626S. [Abstract] [Full Text] [PDF]

				P. D. Coleridge Smith Update on Chronic-Venous-Insufficiency-Induced Inflammatory Processes Angiology, August 1, 2001; 52(1_suppl): S35 - S42. [Abstract] [PDF]

				E. Ernst Pentoxifylline for Intermittent Claudication: A Critical Review Angiology, May 1, 1994; 45(5): 339 - 345. [Abstract] [PDF]

				D. J. Effeney, J. A. Stokes, and H. M. Trenerry The Trials and Tribulations of Pentoxifylline Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1992; 5(2): 123 - 137. [PDF]

				S. M. Cohen and T. Mathews Pentoxifylline in the Treatment of Distal Diabetic Neuropathy Angiology, September 1, 1991; 42(9): 741 - 746. [Abstract] [PDF]

				J. C. Barnett and R. C. Touchon Therapy of Ischemic Cardiomyopathy with Pentoxifylline Angiology, December 1, 1990; 41(12): 1048 - 1052. [Abstract] [PDF]

				D. M. Cummings and S. K. Ballas Effects of Pentoxifylline and Metabolite on Red Blood Cell Deformability as Measured by Ektacytometry Angiology, February 1, 1990; 41(2): 118 - 123. [Abstract] [PDF]

				M. De Felice, P. Gallo, and G. Masotti Current Therapy of Peripheral Obstructive Arterial Disease. The Non-Surgical Approach Angiology, January 1, 1990; 41(1): 1 - 11. [Abstract] [PDF]

				J. E. Crowder, J. B. Cohn, J. P. Savitsky, D. L. Morgan, M.S. J. Slywka, B. L. Cobert, S. W. Hryniewicki, R. T. Piccirillo, and C. S. Wilcox Efficacy and Safety of Pentoxifylline in Geriatric Patients with Intermittent Claudication Angiology, September 1, 1989; 40(9): 795 - 802. [Abstract] [PDF]

				G. Rudofsky, K.F. Haussler, H.P. Kunkel, H. Schneider-May, F. Spengel, O. Symann, and H.-J. Werner Intravenous Treatment of Chronic Peripheral Occlusive Arterial Disease: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial of Pentoxifylline Angiology, July 1, 1989; 40(7): 639 - 649. [Abstract] [PDF]

				R. W. Schwartz, N. M. Logan, P. J. Johnson, W. E. Strodel, J. G. Fine, A. Kazmers, and G. L. Hyde Pentoxifylline Increases Extremity Blood Flow in Diabetic Atherosclerotic Patients Arch Surg, April 1, 1989; 124(4): 434 - 437. [Abstract] [PDF]

				R. Karnik, A. Valentin, C. Stollberger, and J. Slany Effects of Naftidrofuryl in Patients With Intermittent Claudication Angiology, March 1, 1988; 39(3): 234 - 240. [Abstract] [PDF]

				R. Lee Kirby and R. W. Marlow Reliability of Walking Endurance with an Incremental Treadmill Test Angiology, July 1, 1987; 38(7): 524 - 529. [Abstract] [PDF]